EGFR and non-small cell lung carcinoma: Beyond the classic cytotoxic chemotherapy drugs available, epidermal growth factor receptor (EGFR) inhibitors (EGFRi) have been consolidated as the most important class of targeted therapy against NSCLC [5, 6, 7].